Centene Future Growth
Future criteria checks 1/6
Centene is forecast to grow earnings and revenue by 3.3% and 5.5% per annum respectively. EPS is expected to grow by 8.1% per annum. Return on equity is forecast to be 12.8% in 3 years.
Key information
3.3%
Earnings growth rate
8.1%
EPS growth rate
Healthcare earnings growth | 17.6% |
Revenue growth rate | 5.5% |
Future return on equity | 12.8% |
Analyst coverage | Good |
Last updated | 18 Jan 2025 |
Recent future growth updates
Recent updates
Centene: Attractive Risk-Reward For A Growing Company At A Value Price
Jan 02Does Centene (NYSE:CNC) Have A Healthy Balance Sheet?
Dec 05Centene: Should Have Followed My Original Thesis, But A Buy For Q3 2024
Oct 22Centene Corporation (NYSE:CNC) Screens Well But There Might Be A Catch
Oct 14Should You Be Adding Centene (NYSE:CNC) To Your Watchlist Today?
Sep 26Centene (NYSE:CNC) Has Some Way To Go To Become A Multi-Bagger
Sep 08Centene (NYSE:CNC) Seems To Use Debt Quite Sensibly
Aug 20Centene Corporation: Strategic Market Position Amid Favorable Trends, Buy
Aug 20Centene (NYSE:CNC) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Aug 02Here's Why We Think Centene (NYSE:CNC) Is Well Worth Watching
Jun 22A Piece Of The Puzzle Missing From Centene Corporation's (NYSE:CNC) Share Price
Jun 04Returns At Centene (NYSE:CNC) Appear To Be Weighed Down
May 14These 4 Measures Indicate That Centene (NYSE:CNC) Is Using Debt Reasonably Well
Apr 26Centene Corporation Still An Opportunity With An A-Grade Valuation
Mar 31If EPS Growth Is Important To You, Centene (NYSE:CNC) Presents An Opportunity
Mar 15Market Still Lacking Some Conviction On Centene Corporation (NYSE:CNC)
Feb 08Centene: Stay Defensive Amid Economic Uncertainty With This Low-Beta Bargain
Jan 22Centene: Overlooked Healthcare Giant
Nov 21Centene: Solid Performance With Positive Outlook, But Limited Upside Potential
Oct 26Decoding Centene: Why I Think It's Undervalued
Oct 10Centene: Results Impress But Buyers Aren't Swarming Yet
Jul 27Centene Non-GAAP EPS of $0.86 beats by $0.02, revenue of $35.56B beats by $190M
Feb 07Centene: Once Again, With Quality, Now A 'Buy'
Dec 23Centene appoints new leadership; Ken Fasola President of Centene, Dave Thomas CEO of Medicaid
Dec 14Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2027 | 180,647 | 3,634 | 4,391 | 5,600 | 3 |
12/31/2026 | 172,566 | 3,228 | 3,950 | 4,515 | 13 |
12/31/2025 | 168,196 | 3,046 | 3,974 | 5,211 | 15 |
12/31/2024 | 161,194 | 3,110 | 1,731 | 2,315 | 15 |
9/30/2024 | 146,204 | 3,067 | 245 | 958 | N/A |
6/30/2024 | 144,064 | 2,823 | 2,261 | 2,957 | N/A |
3/31/2024 | 142,800 | 2,735 | 2,603 | 3,328 | N/A |
12/31/2023 | 141,266 | 2,702 | 7,254 | 8,053 | N/A |
9/30/2023 | 139,364 | 2,444 | 5,451 | 6,260 | N/A |
6/30/2023 | 138,111 | 2,713 | 7,651 | 8,571 | N/A |
3/31/2023 | 136,941 | 1,483 | 8,392 | 9,379 | N/A |
12/31/2022 | 135,999 | 1,202 | 5,257 | 6,261 | N/A |
9/30/2022 | 132,756 | 2,014 | 7,493 | 8,512 | N/A |
6/30/2022 | 129,228 | 1,860 | 5,985 | 6,982 | N/A |
3/31/2022 | 124,181 | 1,497 | 4,348 | 5,313 | N/A |
12/31/2021 | 118,573 | 1,347 | 3,295 | 4,205 | N/A |
9/30/2021 | 114,130 | 736 | 5,643 | 6,511 | N/A |
6/30/2021 | 111,284 | 720 | 2,863 | 3,757 | N/A |
3/31/2021 | 108,158 | 2,461 | 4,907 | 5,786 | N/A |
12/31/2020 | 104,280 | 1,808 | 4,634 | 5,503 | N/A |
9/30/2020 | 95,764 | 2,029 | 1,008 | 1,871 | N/A |
6/30/2020 | 86,523 | 1,556 | 1,918 | 2,724 | N/A |
3/31/2020 | 78,105 | 845 | -804 | -73 | N/A |
12/31/2019 | 70,807 | 1,321 | 753 | 1,483 | N/A |
9/30/2019 | 68,385 | 1,353 | 784 | 1,500 | N/A |
6/30/2019 | 65,507 | 1,277 | 1,498 | 2,147 | N/A |
3/31/2019 | 61,028 | 1,082 | 71 | 704 | N/A |
12/31/2018 | 56,688 | 900 | 559 | 1,234 | N/A |
9/30/2018 | 52,618 | 889 | 1,708 | 2,318 | N/A |
6/30/2018 | 48,655 | 1,075 | N/A | 1,867 | N/A |
3/31/2018 | 47,201 | 1,029 | N/A | 2,087 | N/A |
12/31/2017 | 45,810 | 828 | N/A | 1,489 | N/A |
9/30/2017 | 44,870 | 853 | N/A | 2,631 | N/A |
6/30/2017 | 43,646 | 796 | N/A | 3,016 | N/A |
3/31/2017 | 42,468 | 713 | N/A | 2,903 | N/A |
12/31/2016 | 37,693 | 562 | N/A | 1,851 | N/A |
9/30/2016 | 32,839 | 416 | N/A | 460 | N/A |
6/30/2016 | 28,062 | 360 | N/A | 40 | N/A |
3/31/2016 | 22,948 | 277 | N/A | 809 | N/A |
12/31/2015 | 21,292 | 356 | N/A | 658 | N/A |
9/30/2015 | 19,854 | 350 | N/A | 827 | N/A |
6/30/2015 | 18,548 | 339 | N/A | 1,206 | N/A |
3/31/2015 | 17,102 | 298 | N/A | 1,016 | N/A |
12/31/2014 | 15,689 | 268 | N/A | 1,223 | N/A |
9/30/2014 | 14,134 | 210 | N/A | 1,023 | N/A |
6/30/2014 | 12,700 | 179 | N/A | 713 | N/A |
3/31/2014 | 11,475 | 172 | N/A | 591 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CNC's forecast earnings growth (3.3% per year) is above the savings rate (2.6%).
Earnings vs Market: CNC's earnings (3.3% per year) are forecast to grow slower than the US market (14.9% per year).
High Growth Earnings: CNC's earnings are forecast to grow, but not significantly.
Revenue vs Market: CNC's revenue (5.5% per year) is forecast to grow slower than the US market (9% per year).
High Growth Revenue: CNC's revenue (5.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CNC's Return on Equity is forecast to be low in 3 years time (12.8%).
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/21 22:40 |
End of Day Share Price | 2025/01/21 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Centene Corporation is covered by 44 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
null null | Argus Research Company |
Hua Ha | Baird |
Ishan Majumdar | Baptista Research |